HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study

被引:3
作者
Kim, So Won [1 ,3 ]
Yu, Hoon [3 ,6 ]
Kim, Younjuong [2 ]
Nam, Kyeng Hyun [2 ]
Chae, Han Kyu [4 ]
Nam, Wook [4 ]
Eom, Dae-Woon [5 ]
Park, Jong Yeon [4 ]
Kim, Sung Jin [3 ,4 ,7 ]
机构
[1] Univ Ulsan, Coll Med, Dept Pharmacol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[3] Univ Ulsan, Biomed Inst Technol, Coll Med, Seoul, South Korea
[4] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Urol, Kangnung, South Korea
[5] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Pathol, Kangnung, South Korea
[6] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Nephrol, Kangnung, South Korea
[7] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Urol, Bangdong Gil 38, Gangneung Si 25440, Gangwon Do, South Korea
基金
新加坡国家研究基金会;
关键词
HER2; neoadjuvant chemotherapy; radical cystectomy; urinary bladder neoplasms; NEOADJUVANT CHEMOTHERAPY; UROTHELIAL CARCINOMA; CELL-CARCINOMA; SUBTYPES; IDENTIFICATION; AMPLIFICATION; TRASTUZUMAB; EXPRESSION; GRADE; BASAL;
D O I
10.1097/JS9.0000000000000859
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Human epidermal growth factor receptor type 2 (HER2) overexpression is a prognostic factor and a therapeutic target for breast cancer; however, anti-HER2 therapies are ineffective in patients with bladder cancer. The authors investigated the effect of HER2 overexpression (HER2(+)) on the prognosis of muscle-invasive bladder cancer (MIBC). Materials and methods: This retrospective cohort study included patients who underwent initial transurethral resection of bladder tumors between 2005 and 2013 and were registered in the Korea National Health Insurance Database, which provides data on overall survival (OS). Sixty-one patients with clinically nonmetastatic de novo MIBC were included in this study. As a subgroup, 33 patients who underwent immediate radical cystectomy (RC) were analyzed. Univariate and multivariate Cox proportional hazards models were used to identify prognostic factors for survival. A multivariable binary logistic regression model was used to identify the favorable T stage. Results: Among the 61 patients with d-MIBC, 14 were HER2(+) and 47 HER2(-). Age less than 70 years [hazard ratio (HR): 0.312, CI: 0.16-0.59, P<0.001] and HER2(+) status (HR: 0.40, CI: 0.19-0.85, P=0.02) were favorable prognostic factors for OS after adjusting for clinical variables. In the RC subgroup, HER2(+) status was a significant predictive factor for the pT2 stage (HR): 36.8, CI: 4.83-797.41, P<0.01). Age less than 70 years (HR: 0.15, CI: 0.05-0.42, P<0.001) and HER2(+) status (HR: 0.11, CI: 0.02-0.54, P=0.01) were favorable prognostic factors for OS after adjusting for RC pathological variables. Conclusions: HER2(+) status could be a marker for an indolent subset of MIBC and could predict favorable survival regardless of RC status. Moreover, HER2(+) status not only consistently predicted a favorable T stage after RC, but also predicted better survival than pathological outcomes.
引用
收藏
页码:847 / 858
页数:12
相关论文
共 39 条
[31]   Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma [J].
Van Allen, Eliezer M. ;
Mouw, Kent W. ;
Kim, Philip ;
Iyer, Gopa ;
Wagle, Nikhil ;
Al-Ahmadie, Hikmat ;
Zhu, Cong ;
Ostrovnaya, Irina ;
Kryukov, Gregory V. ;
O'Connor, Kevin W. ;
Sfakianoss, John ;
Garcia-Grossman, Ilana ;
Kim, Jaegil ;
Guancial, Elizabeth A. ;
Bambury, Richard ;
Bahl, Samira ;
Gupta, Namrata ;
Farlow, Deborah ;
Qu, Angela ;
Signoretti, Sabina ;
Barletta, Justine A. ;
Reuter, Victor ;
Boehm, Jesse ;
Lawrence, Michael ;
Getz, Gad ;
Kantoff, Philip ;
Bochner, Bernard H. ;
Choueiri, Toni K. ;
Bajorin, Dean F. ;
Solit, David B. ;
Gabriel, Stacey ;
D'Andrea, Alan ;
Garraway, Levi A. ;
Rosenberg, Jonathan E. .
CANCER DISCOVERY, 2014, 4 (10) :1140-1153
[32]   Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome [J].
van Rhijn, BWG ;
Vis, AN ;
van der Kwast, TH ;
Kirkels, WJ ;
Radvanyi, F ;
Ooms, ECM ;
Chopin, DK ;
Boevé, ER ;
Jöbsis, AC ;
Zwarthoff, EC .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1912-1921
[33]   Comprehensive molecular characterization of urothelial bladder carcinoma [J].
Weinstein, John N. ;
Akbani, Rehan ;
Broom, Bradley M. ;
Wang, Wenyi ;
Verhaak, Roeland G. W. ;
McConkey, David ;
Lerner, Seth ;
Morgan, Margaret ;
Creighton, Chad J. ;
Smith, Carolyn ;
Kwiatkowski, David J. ;
Cherniack, Andrew D. ;
Kim, Jaegil ;
Pedamallu, Chandra Sekhar ;
Noble, Michael S. ;
Al-Ahmadie, Hikmat A. ;
Reuter, Victor E. ;
Rosenberg, Jonathan E. ;
Bajorin, Dean F. ;
Bochner, Bernard H. ;
Solit, David B. ;
Koppie, Theresa ;
Robinson, Brian ;
Gordenin, Dmitry A. ;
Fargo, David ;
Klimczak, Leszek J. ;
Roberts, Steven A. ;
Au, Jessie ;
Laird, Peter W. ;
Hinoue, Toshinori ;
Schultz, Nikolaus ;
Ramirez, Ricardo ;
Hansel, Donna ;
Hoadley, Katherine A. ;
Kim, William Y. ;
Damrauer, Jeffrey S. ;
Baylin, Stephen B. ;
Mungall, Andrew J. ;
Robertson, A. Gordon ;
Chu, Andy ;
Kwiatkowski, David J. ;
Sougnez, Carrie ;
Cibulskis, Kristian ;
Lichtenstein, Lee ;
Sivachenko, Andrey ;
Stewart, Chip ;
Lawrence, Michael S. ;
Getz, Gad ;
Lander, Eric ;
Gabriel, Stacey B. .
NATURE, 2014, 507 (7492) :315-322
[34]   European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines [J].
Witjes, J. Alfred ;
Bruins, Harman Max ;
Cathomas, Richard ;
Comperat, Eva M. ;
Cowan, Nigel C. ;
Gakis, Georgios ;
Hernandez, Virginia ;
Linares Espinos, Estefania ;
Lorch, Anja ;
Neuzillet, Yann ;
Rouanne, Mathieu ;
Thalmann, George N. ;
Veskimae, Erik ;
Ribal, Maria J. ;
van der Heijden, Antoine G. .
EUROPEAN UROLOGY, 2021, 79 (01) :82-104
[35]  
Wolff AC, 2018, J CLIN ONCOL, V36, P2105, DOI [10.1200/JCO.2018.77.8738, 10.5858/arpa.2018-0902-SA]
[36]   HER2 expression status in diverse cancers: review of results from 37,992 patients [J].
Yan, Min ;
Schwaederle, Maria ;
Arguello, David ;
Millis, Sherri Z. ;
Gatalica, Zoran ;
Kurzrock, Razelle .
CANCER AND METASTASIS REVIEWS, 2015, 34 (01) :157-164
[37]   Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis [J].
Yin, Ming ;
Joshi, Monika ;
Meijer, Richard P. ;
Glantz, Michael ;
Holder, Sheldon ;
Harvey, Harold A. ;
Kaag, Matthew ;
van de Putte, Elisabeth E. Fransen ;
Horenblas, Simon ;
Drabick, Joseph J. .
ONCOLOGIST, 2016, 21 (06) :708-715
[38]   Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Results From the National Cancer Database [J].
Zaid, Harras B. ;
Patel, Sanjay G. ;
Stimson, C. J. ;
Resnick, Matthew J. ;
Cookson, Michael S. ;
Barocas, Daniel A. ;
Chang, Sam S. .
UROLOGY, 2014, 83 (01) :75-80
[39]   Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? [J].
Zargar, Homayoun ;
Zargar-Shoshtari, Kamran ;
Lotan, Yair ;
Shah, Jay B. ;
van Rhijn, Bas W. ;
Daneshmand, Siamak ;
Spiess, Philippe E. ;
Black, Peter .
JOURNAL OF UROLOGY, 2016, 195 (04) :886-891